Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer

Publication
Article
OncologyONCOLOGY Vol 22 No 2
Volume 22
Issue 2

new Mayo Clinic study found that 40% of pancreatic cancer patients are diagnosed with diabetes prior to their pancreatic cancer diagnosis

 

A new Mayo Clinic study found that 40% of pancreatic cancer patients are diagnosed with diabetes prior to their pancreatic cancer diagnosis. The onset of diabetes appears to occur many months (in some cases up to 2 years) prior to cancer diagnosis. This information provides researchers an important clue for earlier detection of pancreatic cancer. The study was published in the January issue of Gastroenterology.

"Our previous studies have shown an association between recent diagnoses of diabetes and pancreatic cancer," says Suresh Chari, MD, a Mayo Clinic gastroenterologist and the study's lead author. "We are now quite convinced that in most patients with pancreatic cancer the diabetes is caused by the cancer and not the other way around. Our next step is to identify a biomarker for pancreatic cancer–induced diabetes in order to screen patients with new-onset diabetes for early pancreatic cancer and provide surgical treatment as quickly as possible."

 

Cost-Effective Screening Test Sought

The study reviewed the medical records of 736 pancreatic cancer patients and 1,875 healthy individuals with fasting blood glucose data in their medical record. The researchers found that 40% of pancreatic cancer patients were diagnosed with diabetes, while only 20% of healthy individuals had fasting blood glucose levels in the diabetic range.

Type 2 diabetes is far more common than pancreatic cancer–induced diabetes. Only 1 in 125 patients over age 50 with new-onset diabetes will be diagnosed with pancreatic cancer. Dr. Chari's team continues work in identifying the differences between pancreatic cancer–induced diabetes and regular type 2 diabetes, seeking a cost-effective means of screening for pancreatic cancer using a blood test that can identify individuals who have new-onset diabetes and are more likely to have pancreatic cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content